Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM17 | P78536 | 8/20 | 0.46 |
| ▸ | FAAH | O00519 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.39 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.39 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.39 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16155981 | 0.91 | ADAM17 (0.40) | ADAM17FAAHOPRM1OPRL1 | |
| SCHEMBL2581589 | 0.86 | ADAM17 (0.43) | ADAM17OPRM1 | |
| SCHEMBL2590397 | 0.81 | ADAM17 (0.49) | ADAM17 | |
| SCHEMBL2594813 | 0.81 | OPRM1 (0.48) | OPRM1OPRL1 | |
| SCHEMBL12175527 | 0.79 | OPRM1 (0.42) | OPRM1 | |
| Hydrochloric Acid SCHEMBL2587755 | 0.78 | OPRM1 (0.41) | OPRM1 | |
| SCHEMBL2589017 | 0.78 | S1PR5 (0.39) | ADAM17MAOB | |
| Hydrochloric Acid SCHEMBL2587759 | 0.74 | HTT (0.54) | OPRM1 | |
| SCHEMBL2589090 | 0.72 | LMNA (0.56) | FAAHOPRM1 | |
| Hydrochloric Acid SCHEMBL2581811 | 0.71 | LMNA (0.55) | OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8859777-B2 | 4-fluoro-4-arylpiperdin-1-yl derivatives as mu opioid function moderators | KINENTIA BIOSCIENCES LLC (US) | 2014-10-14 | — | — | US | disclosed |
| US-20130045165-A1 | 4-FLUORO-4-ARYLPIPERDIN-1-YL DERIVATIVES AS MU OPIOID FUNCTION MODERATORS | KINENTIA BIOSCIENCES, LLC (US) | 2013-02-21 | — | — | US | disclosed |
| WO-2011137331-A2 | 4-FLUORO-4-ARYLPIPERDIN-1-YL DERIVATIVES AS MU OPIOID FUNCTION MODERATORS | KINENTIA BIOSCIENCES LLC (US) | 2011-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130045165-A1 | 4-FLUORO-4-ARYLPIPERDIN-1-YL DERIVATIVES AS MU OPIOID FUNCTION MODERATORS | OPRD1, OPRK1, OPRM1 | ADAM17 4036/4885FAAH 135/4885MAOB 921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.